Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fibroblast growth factor 1 - CardioVascular BioTherapeutics

Drug Profile

Fibroblast growth factor 1 - CardioVascular BioTherapeutics

Alternative Names: Acidic FGF; Cardio Vascu-Grow; CVBT-141A; CVBT-141B; CVBT-141C; CVBT-141D; CVBT-141E; CVBT-141F; CVBT-141G; CVBT-141H; FGF-1(141)

Latest Information Update: 04 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CardioVascular BioTherapeutics Inc
  • Class Anti-ischaemics; Fibroblast growth factors
  • Mechanism of Action Angiogenesis inducing agents; Fibroblast growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Coronary disorders; Diabetic foot ulcer; Wounds
  • No development reported Peripheral vascular disorders
  • Discontinued Back pain; Diabetes mellitus; Ischaemia; Osteoporosis; Stroke

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Peripheral-vascular-disorders in USA (IM, Injection)
  • 04 Oct 2015 Cordis Corporation has been acquired by Cardinal Health
  • 29 Apr 2014 CardioVascular BioTherapeutics suspends a phase II trial in Coronary disorders in USA (NCT00117936)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top